Kwan Chee Chan
The Chinese University of Hong Kong
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kwan Chee Chan.
Hong Kong Medical Journal | 2018
Winnie Yeo; M. Y. Luk; Inda S. Soong; Tony Yiu Sang Yuen; T. Y. Ng; Frankie Mo; Kwan Chee Chan; S. Y. Wong; Janice Tsang; Carmen Leung; J Suen; Roger K.C. Ngan
INTRODUCTION The management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has changed dramatically with the introduction and widespread use of HER2-targeted therapies. There is, however, relatively limited real-world information about the effectiveness and safety of trastuzumab emtansine (T-DM1) in Hong Kong Chinese patients. We assessed the efficacy and toxicity profiles among local patients with HER2-positive advanced breast cancer who had received T-DM1 therapy in the second-line setting and beyond. METHODS This retrospective study involved five local centres that provide service for over 80% of the breast cancer population in Hong Kong. The study period was from December 2013 to December 2015. Patients were included if they had recurrent or metastatic histologically confirmed HER2+ breast cancer who had progressed after at least one line of anti-HER2 therapy including trastuzumab. Patients were excluded if they received T-DM1 as first-line treatment for recurrent or metastatic HER2+ breast cancer. Patient charts including biochemical and haematological profiles were reviewed for background information, T-DM1 response, and toxicity data. Adverse events were documented during chemotherapy and 28 days after the last dose of medication. RESULTS Among 37 patients being included in this study, 28 (75.7%) had two or more lines of anti-HER2 agents and 26 (70.3%) had received two or more lines of palliative chemotherapy. Response assessment revealed that three (8.1%) patients had a complete response, eight (21.6%) a partial response, 11 (29.7%) a stable disease, and 12 (32.4%) a progressive disease; three patients could not be assessed. The median duration of response was 17.3 (95% confidence interval, 8.4-24.8) months. The clinical benefit rate (complete response + partial response + stable disease, ≥12 weeks) was 37.8% (95% confidence interval, 22.2%-53.5%). The median progression-free survival was 6.0 (95% confidence interval, 3.3- 9.8) months and the median overall survival had not been reached by the data cut-off date. Grade 3 or 4 toxicities included thrombocytopaenia (13.5%), raised alanine transaminase (8.1%), anaemia (5.4%), and hypokalaemia (2.7%). No patient died as a result of toxicities. CONCLUSIONS In patients with HER2-positive advanced breast cancer who have been heavily pretreated with anti-HER2 agents and cytotoxic chemotherapy, T-DM1 is well tolerated and provided a meaningful progression-free survival of 6 months and an overall survival that has not been reached. Further studies to identify appropriate patient subgroups are warranted.
Archive | 2014
Yuk-Ming Dennis Lo; Rossa W.K. Chiu; Kwan Chee Chan
Archive | 2008
Yuk-Ming Dennis Lo; Rossa W.K. Chiu; Kwan Chee Chan; Benny Zee; Ka Chun Chong
Archive | 2010
Yuk Ming Dennis Lo; Kwan Chee Chan; Wai Kwun Rossa Chiu; Charles Cantor
Archive | 2009
Yuk-Ming Dennis Lo; Rossa W.K. Chiu; Kwan Chee Chan
Archive | 2008
Yuk-Ming Dennis Lo; Rossa W.K. Chiu; Kwan Chee Chan
Archive | 2007
Yuk Ming Dennis Lo; Rossa W.K. Chiu; Stephen Siu Chung Chim; Chunming Ding; Kwan Chee Chan; Hing Nam Ivy Wong; Ka Chun Ryan Yuen
Archive | 2011
Yuk Ming Dennis Lo; Kwan Chee Chan; Wai Kwun Rossa Chiu; Peiyong Jiang
Archive | 2010
Yuk Ming Dennis Lo; Kwan Chee Chan; Wai Kwun Rossa Chiu; Wenli Zheng
Archive | 2007
Yuk Ming Dennis Lo; Rossa W.K. Chiu; Stephen Siu Chung Chim; Chunming Ding; Kwan Chee Chan; Hing Nam Ivy Wong; Ka Chun Ryan Yuen